Question 1: What diseases are included in cardiovascular and cerebrovascular diseases? Several common cardiovascular and cerebrovascular diseases
1) Hypertension
The dangers of high blood pressure: Long-term sustained high blood pressure can lead to systemic arteriosclerosis and increased vascular resistance. It can also cause damage to important organs such as the heart, brain, kidneys and the occurrence of related diseases. The most common ones are: stroke, myocardial infarction and renal failure.
2) Coronary heart disease
Coronary heart disease is the abbreviation of coronary atherosclerotic heart disease. Myocardial ischemic disease caused by insufficient blood supply due to the obstruction of the coronary arteries, the most important arteries that nourish the heart, by atherosclerotic stenosis, or on this basis, spasm, thrombosis, etc., causing blood flow obstruction and insufficient blood supply.
Dangers of coronary heart disease
When the symptoms of cardiac ischemia caused by coronary heart disease become more and more serious, angina pectoris, myocardial infarction, and even death may occur.
3) Stroke
Commonly known as stroke, medically also known as cerebrovascular accident or acute cerebrovascular disease, including cerebral hemorrhage, cerebral thrombosis, cerebral embolism, subarachnoid space Hemorrhage and other acute cerebrovascular diseases.
Dangers of stroke
Stroke can cause hemiplegia or death and is the main cause of death and disability among middle-aged and elderly people. Once the disease occurs, most are difficult to completely cure.
4) Hyperlipidemia
The dangers of hyperlipidemia
Hyperlipidemia is the cause of atherosclerotic diseases in the human body (such as coronary heart disease, cerebral infarction and Peripheral vascular thromboembolic disease) is a major risk factor and therefore has great harm to human health.
5) How to prevent and treat cardiovascular and cerebrovascular diseases. You must maintain a stable and peaceful mood in life. You must insist on taking Xinlijian vegetable capsules every day to replenish vitality, strengthen the heart, and save the heart and brain, twice a day. , 3 capsules each time. To promote tissue repair and regeneration, anti-aging, lower blood lipids and protect liver, hematopoiesis, lower blood sugar, etc.; replenish qi and activate blood, make blood clear and flow smoothly; replenish qi and save the brain, restore the ability of listening, speaking, reading, writing and eating; Replenish qi and nourish the heart, make the heart live and beat.
In addition, the focus of prevention of cardiovascular and cerebrovascular diseases is to change unhealthy lifestyles and cultivate healthy lifestyles. The focus is on four aspects: arranging meals appropriately, adhering to appropriate exercise, changing bad behaviors and maintaining a peaceful mind.
Question 2: List of cardiovascular and cerebrovascular pharmaceutical stocks 1. Jiangsu Wuzhong Company is currently developing a national first-class biological anti-cancer new drug, recombinant human endostatin injection, and obtained R&D and industrialization projects. With special fund support for the transformation of scientific and technological achievements in the province where the company is located, the project contract was issued to the company on November 24, 2010. The project is currently in the stage of applying for Phase III clinical research.
2. Haixin Co., Ltd.
The media disclosed that the new drug for the treatment of rectal cancer - "antigen-sensitized human dendritic cells (APDC)" will soon receive Phase III clinical approval . Pure conceptual hype with no performance support
3. North China Pharmaceuticals
The company’s anti-cancer drug has entered the second phase of clinical trials (according to the company’s product development plan, combined with relocation and new campus Based on the construction needs and the company's technical reserves, the company plans to implement a new anti-cancer drug cooperation project. This project is the original research and development product of the partner and has been authorized by two national invention patents. The total investment of the project is 10,000 yuan. The plan is to be implemented in two phases: the first phase involves a phased investment of 35 million yuan before December 2010 to exclusively receive the clinical approval documents, patents and myxobacterial technology platform of the product, and at the same time, an investment of 15 million yuan to cooperate in completing phase III clinical trials. , with a total investment of 50 million yuan; the second phase of the project is the construction period of the industrialization project. It is planned to establish a joint venture company when the time is ripe based on the progress of the first phase project. The company will invest in the shares, accounting for 65% of the shares, and the transferor will use technology We will acquire 35% of the shares. We will also carry out production site planning and facility construction, pass GMP acceptance, obtain production approval, and complete Phase IV clinical trials. We plan to achieve large-scale production in May 2011, with an estimated investment of 58 million yuan.
The project construction period is 1 year, and the sales revenue is expected to be 180 million yuan in the third year after the project is completed) 4. Hisun Pharmaceutical
The company is an antibiotic manufacturer of epirobicin hydrochloride and oxaliplatin As the leading anti-tumor drug, tacrolimus is the first generic drug to be launched in Europe, which will bring considerable profits to the company; a large number of generic drugs will be launched in the United States in the future, which is expected to repeat Ranbaxy's high growth process from 1999 to 2004. . The rapid growth driven by preparation exports will bring huge returns to investors
5. Fengyuan Pharmaceutical
The development prospects of anti-cancer implants, Fengyuan Pharmaceutical in July this year The industry teamed up with Anhui Zhongren Technology to develop anti-cancer drugs. The two parties signed a "Joint Venture Contract" and established a joint venture to engage in the research, development, production and sales of new implantable drugs. Among them, Fengyuan Pharmaceutical contributed 45.5 million yuan in cash and 30 acres of land use rights (total price of 50 million yuan), accounting for 60% of the joint venture's registered capital; Zhongren Technology used cisplatin and methotrexate anti-cancer implants The relevant patented technology, clinical approval documents and all production technologies of the agent were valued at 33.33 million yuan as investment, accounting for 40% of the registered capital of the joint venture company. Relevant parties expect that implantable sustained-release cisplatin will be available for sale in the second half of 2012, and implantable sustained-release methotrexate will be available for sale in the second half of 2013. The new product can not only reduce the systemic toxic effects of anti-cancer drugs, but also selectively increase the local drug concentration in the tumor and enhance the therapeutic effect of anti-cancer drugs, which is expected to become a new profit growth point
6. Changchun High-tech
The company's Tα1 market potential national first-class new drug launched this year. The amino acid sequence and biological activity of this product are completely consistent with foreign chemical synthesis products. Due to the high technical difficulty of developing this project, so far, no genetically recombinant Tα1 has been launched at home or abroad.
Thymosin α1 has three main clinical applications:
(1) Treatment of viral infectious diseases, especially effective against hepatitis B and hepatitis C; < /p>
(2) Treatment of some malignant tumors such as lung cancer and melanoma;
(3) Enhancement of the body’s immune function, etc. It can form a sales market of 4.5 billion yuan
7. Pien Tze Huang
In 2004, the anti-cancer research of Pien Tze Huang capsule was included in the national 863 plan. Pien Tze Huang can significantly inhibit digestive system cancer cells. The formula National top secret, small market value
8. Hengrui Medicine
Liver cancer has the highest mortality rate among all cancers. Tigeo capsule is an oral anti-cancer agent of fluorouracil derivatives. It includes two types of modulators: tegafur (FT) and CDHP (CDHP) and otiracil (Oxo), which are used to treat gastric cancer, rectal cancer, head and neck cancer, non-small cell lung cancer, metastatic breast cancer and pancreatic cancer. The company was officially approved at the end of August 2010 and production started in September. This year and next, it will become a first-line product in the anti-tumor product line and will usher in rapid growth. It is expected that the company's product... >>
Question 3: Examination on drug treatment of cardiovascular and cerebrovascular diseases. Single choice answer: 1B 2C 3D 4B
Multiple choice ：1ABC 2ACD 3ABCD 4ABCD 5ACD 6ABCD
Submit 70 points